AstraZeneca PLC aims for $80 billion revenue by 2030 through strong growth in oncology, biopharmaceuticals, and rare diseases ...

The pharmaceutical giant expects overall sales and core earnings per share to rise by a high-teens percentage at constant ...

Profit after tax came in ₹38.4 crore in Q2 of FY25, a recovery from a net loss of ₹11.8 crore in the first quarter of this ...

AstraZeneca’s growth was driven by its portfolio of products in the oncology, biopharmaceuticals and rare disease segments ...

AstraZeneca ( (AZN) ) has released its Q3 earnings. Here is a breakdown of the information AstraZeneca presented to its investors. AstraZeneca ...

AstraZeneca is set to report its third-quarter 2024 earnings Tuesday morning. The company's Q2 performance suggests strong ...

Smith also points out that the focus on Dato-DXd has overshadowed AstraZeneca’s promising non-oncology pipeline, which is expected to deliver significant developments between 2025 and 2028.

CFO Bhavana Agrawal highlighted the company’s steady growth in India, attributing it to consistent progress in oncology, ...

AstraZeneca and Daiichi Sankyo have submitted a new Biologics License Application (BLA) for accelerated approval in the US ...

AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...

The company is also raising its full-year guidance to $14.9 billion in adjusted EBITDA, an 8.8% increase from its last ...